Peptides for TBI Recovery: Preclinical Research
Peptides for TBI
69 million TBI cases/year globally
Traumatic brain injury affects an estimated 69 million people per year worldwide, yet no approved drug targets the secondary injury cascade that drives long-term damage. Preclinical peptide research is changing that equation.
Dewan et al., Journal of Neurosurgery, 2019
Dewan et al., Journal of Neurosurgery, 2019
View as imageEvery Phase III clinical trial for traumatic brain injury neuroprotection has failed. Progesterone, erythropoietin, citicoline, magnesium sulfate: each showed preclinical promise and each produced null results in large human trials. That record of failure defines the challenge facing peptides for TBI recovery. Against that backdrop, at least five distinct peptide classes have produced positive results in animal TBI models: BPC-157, cerebrolysin, GLP-1 receptor agonists, semax, and mitochondrial-targeted peptides like SS-31. This article reviews the preclinical evidence for each, examines their distinct mechanisms, and identifies the therapeutic windows that may determine whether any of them reach human patients.
Key Takeaways
- BPC-157 reduced unconsciousness duration and mortality in mice with weight-drop TBI at doses as low as 10 ng/kg, with brain edema and hemorrhagic lesions substantially reduced on histology (Tudor et al., 2010).[1]
- Sustained-release exenatide (a GLP-1 agonist) attenuated blast TBI-induced cognitive deficits in mice when given either before or after injury, reducing neuroinflammatory markers and neuronal loss (Tweedie et al., 2016; Bader et al., 2019).[2][4]
- SS-31, a mitochondria-targeted tetrapeptide, reversed mitochondrial dysfunction and reduced cortical lesion volume by approximately 30% in a controlled cortical impact model (Zhu et al., 2018).[3]
- Cerebrolysin modulated BDNF, NGF, VEGF, and IGF-1 in preclinical brain injury models, and is the only peptide preparation in this review with existing clinical trial data in neurological conditions (Rejdak et al., 2023).[8]
- A 2025 narrative review identified incretin mimetics (GLP-1, GIP, and glucagon receptor agonists) as the peptide class closest to clinical translation for TBI, based on the existing safety data from diabetes and obesity approvals (Sipos et al., 2025).[12]
- Semaglutide inhibited neuronal apoptosis and improved cognitive function in a 2026 mouse TBI model, working through SIRT1/FOXO3a signaling rather than metabolic pathways (Chen et al., 2026).[13]
Why TBI neuroprotection has failed so far
TBI is not a single event. The initial mechanical injury (primary injury) triggers a secondary cascade that unfolds over hours to weeks: excitotoxicity from glutamate release, mitochondrial dysfunction, neuroinflammation mediated by microglia and astrocytes, blood-brain barrier breakdown, and delayed neuronal apoptosis. Every failed Phase III trial targeted one element of this cascade with a single-mechanism drug.
Peptides offer a different proposition. Many neuroprotective peptides act on multiple pathways simultaneously. BPC-157 modulates the nitric oxide system, serotonin pathways, and growth factor expression. GLP-1 agonists reduce oxidative stress, suppress neuroinflammation, and promote neuronal survival through overlapping but distinct mechanisms.[5] Cerebrolysin, as a peptide mixture, mimics multiple neurotrophic factors at once.[8] Whether this multi-target profile translates into clinical advantage remains unproven, but it explains the sustained research interest.
Corrigan et al. (2016) documented another dimension of TBI pathology: neurogenic inflammation. After TBI, sensory neuropeptides including substance P and calcitonin gene-related peptide (CGRP) are released from perivascular nerve terminals, increasing blood-brain barrier permeability and amplifying the classical inflammatory response.[10] Safwat et al. (2023) expanded on this, showing that substance P levels surge within hours of TBI and correlate with edema severity, making neuropeptide signaling both a driver of damage and a potential therapeutic target.[9]
BPC-157: the gastric pentadecapeptide in brain trauma
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice. It has been studied extensively for gastrointestinal healing, tendon repair, and organ protection in rodent models. Its TBI evidence comes primarily from the Tudor et al. (2010) study.[1]
The model. Tudor's group used a weight-drop TBI model in mice, delivering calibrated force impulses ranging from 0.068 to 0.159 Newton-seconds. BPC-157 was administered intraperitoneally at two doses: 10 micrograms/kg and 10 nanograms/kg.
Prophylactic results. When given 30 minutes before injury, both BPC-157 doses improved the conscious/unconscious/death ratio across all force levels tested (0.068 to 0.145 Ns). The higher dose maintained effectiveness even at the maximum force impulse (0.159 Ns).
Post-injury results. BPC-157 administered immediately before injury was beneficial at moderate force (0.093 Ns). For more severe injuries, beneficial effects appeared within 5 minutes (0.130 Ns), 20 minutes (0.145 Ns), and 30 minutes (0.159 Ns) post-administration, suggesting a time-dependent therapeutic window that narrows with injury severity.
Histological findings. Treated animals showed less intense subarachnoid and intraventricular hemorrhage, reduced brain laceration, and considerably improved brain edema compared to controls.
Vukojevic et al. (2020) extended BPC-157's brain evidence with a hippocampal ischemia/reperfusion model in rats, demonstrating reduced hippocampal damage and improved outcomes after cerebrovascular injury.[7] Sikiric et al. (2023) reviewed the broader BPC-157 brain-gut axis evidence, proposing that BPC-157's neuroprotective effects may involve modulation of the dopamine and serotonin systems alongside its established NO-system interactions.[15]
Limitations. All BPC-157 TBI data comes from a single research group (Sikiric's laboratory in Zagreb). There are no independent replications. The peptide has no completed human trials for any neurological indication. The BPC-157 and TBI article covers this evidence in greater depth, including the regulatory context of the FDA's Category 2 classification.
GLP-1 receptor agonists: repurposing diabetes drugs for the brain
Glucagon-like peptide-1 (GLP-1) receptor agonists are approved worldwide for type 2 diabetes and obesity. The discovery that GLP-1 receptors exist in the brain, particularly in the hippocampus, cortex, and brainstem, opened a second line of investigation: can these peptides protect neurons after injury?
Glotfelty et al. (2019) published the foundational review making the case for incretin mimetics in TBI. They identified five mechanisms relevant to secondary brain injury: reduction of oxidative stress, suppression of neuroinflammation, inhibition of apoptosis, improvement of mitochondrial function, and promotion of neuronal survival and neurogenesis.[5]
Blast TBI model. Tweedie et al. (2016) tested the GLP-1 agonist exenatide in a blast TBI model in mice, simulating the type of injury common in military personnel. Both pre-injury and post-injury exenatide treatment attenuated cognitive deficits on behavioral testing and reduced markers of neuroinflammation and neuronal loss in the hippocampus.[2]
Sustained-release formulation. Bader et al. (2019) tested PT302, a sustained-release exenatide formulation, in a mild TBI mouse model. The sustained-release version maintained therapeutic drug levels for longer periods and improved spatial memory on Morris water maze testing. The study also characterized pharmacokinetics, showing that PT302 achieved brain concentrations sufficient for receptor activation.[4]
Triagonist approach. Li et al. (2020) tested a monomeric peptide that simultaneously activates GLP-1, GIP, and glucagon receptors in cellular and rodent TBI models. The triagonist showed neurotrophic and neuroprotective effects, reducing neuronal death and inflammation more effectively than single-receptor agonists in cell culture. In animal models, it improved both histological and behavioral outcomes.[6]
Semaglutide. Chen et al. (2026) demonstrated that semaglutide, the active compound in Ozempic and Wegovy, inhibited neuronal apoptosis and improved cognitive function in mice after TBI. The mechanism involved activation of the SIRT1/FOXO3a pathway rather than the metabolic pathways that drive its diabetes and weight loss effects, suggesting a distinct neuroprotective action.[13]
Clinical translation prospect. Sipos et al. (2025) published a narrative review arguing that incretin mimetics represent the most translatable peptide class for TBI therapy because they already have extensive human safety data from cardiovascular and metabolic trials. The existing safety profiles, established manufacturing, and known pharmacokinetics could accelerate the regulatory pathway compared to novel peptides.[12]
Limitations. Animal TBI models do not replicate the heterogeneity of human TBI. Blast models are relevant to military injury but may not predict outcomes in civilian concussion or motor vehicle accidents. The optimal timing, dose, and duration of GLP-1 agonist treatment for brain injury remain undefined.
Cerebrolysin: the neurotrophic peptide mixture
Cerebrolysin is a porcine brain-derived peptide preparation containing approximately 20% biologically active neuropeptides (all below 10 kDa) and 80% free amino acids. It is the only peptide in this review with clinical trial data in neurological conditions, though not specifically for TBI.
Rejdak et al. (2023) reviewed cerebrolysin's neurotrophic factor modulation in the context of dementia, stroke, and TBI. In preclinical brain injury models, cerebrolysin upregulated brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1), while suppressing tumor necrosis factor-alpha (TNF-alpha). This combination of neurotrophic stimulation and anti-inflammatory activity addresses multiple arms of the secondary injury cascade simultaneously.[8]
The peptide mixture crosses the blood-brain barrier after intravenous administration. In stroke models, cerebrolysin has been tested in clinical trials, with mixed but generally positive signals on functional recovery. For TBI specifically, the preclinical data is mechanistic rather than outcome-based: cerebrolysin modulates the right pathways, but dedicated TBI animal studies with behavioral endpoints are limited compared to the GLP-1 agonist literature.
Limitations. Cerebrolysin requires intravenous administration, limiting its use to clinical settings. As a complex biological mixture, batch-to-batch consistency is a concern. It is not approved in the United States. The TBI-specific evidence is primarily extrapolated from stroke and dementia research rather than dedicated TBI models.
Semax: the ACTH fragment with neurotrophic effects
Semax is a synthetic heptapeptide analog of adrenocorticotropic hormone (ACTH) fragments 4-10, with an added Pro-Gly-Pro tripeptide that extends its half-life. Developed in Russia for stroke and cognitive impairment, semax's relevance to TBI stems from its ability to upregulate neurotrophic factors in the brain.
Dolotov et al. (2006) demonstrated that semax increased BDNF and its receptor TrkB expression in the rat hippocampus, frontal cortex, and other brain regions. The upregulation was dose-dependent and region-specific, with the hippocampus and basal forebrain showing the strongest responses.[14] BDNF is a critical mediator of neuronal survival and synaptic plasticity after brain injury, and its depletion correlates with worse TBI outcomes in animal models.
Romanova et al. (2006) tested semax directly in an experimental cerebral ischemia model (which shares pathological features with TBI including excitotoxicity and neuronal death). Semax demonstrated both neuroprotective and antiamnesic effects, reducing infarct volume and preserving spatial memory function.[11]
Limitations. Semax has been studied primarily in Russian research institutions, with limited replication in Western laboratories. It is approved as a medication in Russia but has no regulatory status in the US, EU, or other major markets. The ischemia evidence, while relevant to TBI pathophysiology, is not a direct TBI study.
SS-31: targeting mitochondrial dysfunction
SS-31 (also known as elamipretide or Bendavia) is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates in the inner mitochondrial membrane. Mitochondrial dysfunction is a central driver of secondary injury after TBI: when mitochondria fail, they release reactive oxygen species and trigger apoptotic cascades.
Zhu et al. (2018) tested SS-31 in a controlled cortical impact (CCI) TBI model in rats. The results were substantial: SS-31 reversed TBI-induced mitochondrial dysfunction, reduced cortical lesion volume by approximately 30%, and improved neurological function scores. The mechanism involved restoration of mitochondrial membrane potential and reduction of oxidative stress markers in the pericontusional cortex.[3]
SS-31's specificity is notable. Rather than acting broadly on neuroinflammation or neurotrophic pathways, it targets one critical node in the secondary injury cascade: the mitochondrion. This precision may be an advantage (clear mechanism, measurable biomarkers) or a limitation (TBI's multi-pathway pathology may require multi-target interventions).
Limitations. The SS-31 TBI evidence is from a single CCI study. Elamipretide has been tested in human clinical trials for mitochondrial myopathy (Barth syndrome), providing safety data, but no TBI-specific human studies exist.
Intranasal delivery: solving the access problem
One of the fundamental challenges in TBI peptide therapy is delivery. The blood-brain barrier, even when disrupted by injury, limits how much peptide reaches injured neurons after systemic administration.
Yanamadala et al. (2024) addressed this with an intranasal delivery approach. Using a cell-penetrating therapeutic peptide, they demonstrated that intranasal administration enhanced brain delivery, reduced neuroinflammation, and improved neurological outcomes in a TBI model. The intranasal route bypasses the blood-brain barrier entirely by accessing the brain through the olfactory and trigeminal nerve pathways.[11]
This delivery innovation matters because it could determine which peptides ultimately succeed clinically. A peptide with modest neuroprotective activity but excellent brain penetration via intranasal delivery could outperform a stronger neuroprotector that cannot reach injured tissue in sufficient concentrations.
The intranasal approach is particularly relevant for semax, which is already administered intranasally in clinical practice in Russia, and for smaller peptides like BPC-157 whose molecular weight (1419 Da) falls within the range amenable to nasal absorption. For larger peptide preparations like cerebrolysin, intravenous administration remains the only viable route, which confines its use to hospital settings and limits its application in field or outpatient TBI management.
Comparing the peptide candidates
Each peptide class targets different aspects of the TBI secondary cascade:
| Peptide | Primary Mechanism | TBI Model | Administration | Human Safety Data |
|---|---|---|---|---|
| BPC-157 | Multi-pathway (NO, serotonin, growth factors) | Weight-drop (mice) | IP injection | None for neuro |
| GLP-1 agonists | Anti-inflammatory, anti-apoptotic, neurotrophic | Blast, CCI (mice) | SC injection | Extensive (diabetes/obesity) |
| Cerebrolysin | Neurotrophic factor mimicry (BDNF, NGF, VEGF) | Stroke/ischemia models | IV infusion | Clinical trials (stroke, dementia) |
| Semax | BDNF/TrkB upregulation | Cerebral ischemia (rats) | Intranasal | Approved in Russia |
| SS-31 | Mitochondrial membrane stabilization | CCI (rats) | IP injection | Phase II (Barth syndrome) |
This table reveals an inverse relationship in the current evidence: the peptides with the most direct TBI data (BPC-157) have the least human safety data, while the peptides with extensive human safety profiles (GLP-1 agonists) have the most translational potential but are still early in TBI-specific investigation.
The therapeutic window problem
Timing may matter more than which peptide is used. Tudor et al. (2010) showed that BPC-157's effectiveness varied with injury severity: at moderate force, immediate administration was sufficient, while severe injuries required treatment within 5 to 30 minutes.[1] Tweedie et al. (2016) found that exenatide worked with both pre-injury and post-injury dosing, suggesting a wider therapeutic window for GLP-1 agonists.[2]
The secondary injury cascade evolves over a timeline of hours to weeks. Excitotoxicity peaks within minutes to hours. Neuroinflammation escalates over hours to days. Apoptosis continues for days to weeks. A peptide that addresses early excitotoxicity (SS-31's mitochondrial protection) may need to be paired with one that addresses later neuroinflammation (GLP-1 agonists, cerebrolysin) for optimal effect. Whether combination peptide therapy would be additive, synergistic, or complicated by drug interactions is unexplored territory.
For a deeper examination of timing considerations, see our companion article on the therapeutic window for neuroprotective peptides after brain injury.
What these animal results mean and do not mean
The preclinical peptide evidence for TBI recovery is genuinely promising. Multiple peptide classes, working through distinct mechanisms, have reduced brain damage and improved functional outcomes in animal models. That convergence of evidence from different laboratories, different peptides, and different TBI models carries more weight than any single study.
The evidence does not support the claim that any peptide treats TBI in humans. The history of TBI drug development is littered with compounds that worked in rodents and failed in people. The reasons include species differences in brain physiology, the heterogeneity of human TBI (no two brain injuries are identical), the difficulty of matching animal model timing to real-world clinical scenarios, and the gap between controlled laboratory conditions and emergency department reality.
GLP-1 agonists hold a structural advantage in the translational pathway: they are already prescribed to millions of people, their safety profiles are well-characterized, and repurposing trials could proceed without the full preclinical development timeline required for novel peptides. Whether that advantage translates into clinical TBI trials in the near term depends on funding priorities, regulatory decisions, and the willingness of pharmaceutical companies to pursue a neuroprotection indication with a 100% historical failure rate.
The peptides with the least translational infrastructure (BPC-157) face the longest path to clinical testing. BPC-157 has no completed human trial for any indication, no pharmaceutical sponsor, and an FDA Category 2 classification that complicates its regulatory pathway. The preclinical TBI data from Tudor et al. (2010) is now 16 years old with no published follow-up. Semax occupies a middle ground: approved in one country (Russia) with clinical experience in stroke, but lacking the Western regulatory infrastructure and large-scale trial data that would support a TBI indication elsewhere. Cerebrolysin has the broadest clinical experience (approved in 40+ countries for neurological indications) but has never been tested in a dedicated TBI randomized controlled trial.
The most honest assessment of this field is that peptides for TBI recovery remain a preclinical story with multiple promising leads and no clinical proof. The convergence of evidence across peptide classes is encouraging. The gap between animal models and human TBI treatment is not.
The Bottom Line
Preclinical research has identified at least five peptide classes with neuroprotective activity in TBI animal models: BPC-157, GLP-1 receptor agonists, cerebrolysin, semax, and SS-31. Each targets different elements of the secondary injury cascade, from mitochondrial dysfunction to neuroinflammation to neurotrophic factor depletion. GLP-1 agonists, particularly semaglutide and exenatide, represent the closest pathway to clinical translation because of their existing human safety data. No peptide has been tested in a human TBI trial, and the complete failure of all prior TBI neuroprotection drugs in Phase III demands caution about translating rodent success to human outcomes.